354P NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302)
Andrew L. Coveler(University of Washington), T. R. J. Evans, Mary Linton B. Peters(Beth Israel Deaconess Medical Center), Jordan Berlin(Dana-Farber Cancer Institute), Kristen K. Ciombor(Vanderbilt University Medical Center), Michelle Myers(Nucana (United Kingdom)), Aimery de Gramont(Institut Hospitalier Franco Britannique), J. Graham(NHS Greater Glasgow and Clyde), Sarah P. Blagden(Churchill Hospital), H. Marijon Jourdier(Institut Hospitalier Franco Britannique), J. Bloss(Nucana (United Kingdom)), Aglaia Skolariki(MRC Clinical Trials Unit at UCL), Seth A. Cohen(University of Washington), E.M. Oelmann(Nucana (United Kingdom))
Cited by 3
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k